Syndax Pharmaceuticals (SNDX) Finished Goods (2024 - 2026)

Syndax Pharmaceuticals' Finished Goods history runs 3 years deep, the most recent figure standing at $1.4 million for Q1 2026.

• On a quarterly basis, Finished Goods rose 1284.0% year-over-year to $1.4 million in Q1 2026; TTM through Mar 2026 was $1.4 million, a 1284.0% increase from a year earlier, with the FY2025 full-year figure at $1.6 million, up 4386.11% from the prior year.
• Finished Goods declined to $1.4 million in Q1 2026 per SNDX's latest filing, from $1.6 million in the prior quarter.
• Across five years, Finished Goods topped out at $2.2 million in Q2 2025 and bottomed at $36000.0 in Q4 2024.
• The 3-year median for Finished Goods is $1.5 million (2025), against an average of $1.3 million.
• Across the five-year window, Finished Goods soared 4386.11% in 2025 and surged 1284.0% in 2026, its largest moves.
• Year by year, Finished Goods stood at $36000.0 in 2024, then surged by 4386.11% to $1.6 million in 2025, then dropped by 14.3% to $1.4 million in 2026.
• Per Business Quant, the three latest SNDX Finished Goods figures stand at $1.4 million (Q1 2026), $1.6 million (Q4 2025), and $2.2 million (Q3 2025).